Drug intelligence / Profile preview

CETLUKAST

Development stage: Unknown
Lead developer: Wellmed
Modality: Small Molecules
Administration: Oral

Overview

**CETLUKAST** is a Wellmed branded fixed-dose oral tablet containing levocetirizine dihydrochloride 5 mg and montelukast 10 mg. Levocetirizine is a selective histamine H1-receptor antagonist, while montelukast is a selective cysteinyl leukotriene receptor 1 antagonist; together, these small molecules suppress histamine- and leukotriene-mediated allergic symptoms. Wellmed lists CETLUKAST as a marketed tablet product in 10 × 10 Alu-Alu packaging. ([wellmedpharma.com](https://www.wellmedpharma.com/product/cetlukast/))

Brand names: CETLUKAST
Other names: levocetirizine + montelukast

Targets

CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on CETLUKAST.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CETLUKAST.

Explore the full profile